NYSEArca - Delayed Quote USD

SPDR S&P MIDCAP 400 ETF Trust (MDY)

529.80 0.00 (0.00%)
At close: April 24 at 4:00 PM EDT
530.42 +0.62 (+0.12%)
After hours: April 24 at 7:59 PM EDT
Loading Chart for MDY
DELL
  • Previous Close 529.80
  • Open 529.51
  • Bid --
  • Ask --
  • Day's Range 526.32 - 532.06
  • 52 Week Range 424.22 - 558.34
  • Volume 768,771
  • Avg. Volume 920,020
  • Net Assets 22.4B
  • NAV 529.82
  • PE Ratio (TTM) 15.21
  • Yield 1.07%
  • YTD Daily Total Return 4.62%
  • Beta (5Y Monthly) 1.04
  • Expense Ratio (net) 0.24%

The Trust seeks to achieve its investment objective by holding a portfolio of the common stocks that are included in the index (the “Portfolio”), with the weight of each stock in the Portfolio substantially corresponding to the weight of such stock in the index.

SPDR State Street Global Advisors

Fund Family

Mid-Cap Blend

Fund Category

22.4B

Net Assets

1995-05-04

Inception Date

Performance Overview: MDY

Trailing returns as of 4/23/2024. Category is Mid-Cap Blend.

YTD Return

MDY
4.62%
Category
9.21%
 

1-Year Return

MDY
17.57%
Category
22.48%
 

3-Year Return

MDY
3.20%
Category
6.45%
 

People Also Watch

Holdings: MDY

Top 10 Holdings (6.52% of Total Assets)

SymbolCompany% Assets
VST
Vistra Corp. 0.86%
WSM
Williams-Sonoma, Inc. 0.75%
RS
Reliance, Inc. 0.71%
CSL
Carlisle Companies Incorporated 0.70%
GDDY
GoDaddy Inc. 0.61%
EME
EMCOR Group, Inc. 0.60%
GGG
Graco Inc. 0.58%
LII
Lennox International Inc. 0.57%
SAIA
Saia, Inc. 0.57%
PSTG
Pure Storage, Inc. 0.57%

Sector Weightings

SectorMDY
Industrials   21.14%
Technology   11.34%
Healthcare   8.13%
Real Estate   7.73%
Energy   5.79%
Utilities   3.17%

Related ETF News

Research Reports: MDY

  • Analyst Report: Biogen Inc.

    Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

    Rating
    Price Target
     
  • Analyst Report: Netflix, Inc.

    Netflix’s relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with almost 250 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm recently began introducing ad-supported subscription plans, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.

    Rating
    Price Target
     
  • Analyst Report: Meta Platforms, Inc.

    Meta is the world’s largest online social network, with nearly 4 billion family of apps monthly active users. Users engage with each other in different ways, exchanging messages and sharing news events, photos, and videos. The firm’s ecosystem consists mainly of the Facebook app, Instagram, Messenger, WhatsApp, and many features surrounding these products. Users can access Facebook on mobile devices and desktops. Advertising revenue represents more than 90% of the firm’s total revenue, with more than 45% coming from the U.S. and Canada and over 20% from Europe.

    Rating
    Price Target
     
  • Analyst Report: Amazon.com, Inc.

    Amazon is a leading online retailer and one of the highest-grossing e-commerce aggregators, with $386 billion in net sales and approximately $578 billion in estimated physical/digital online gross merchandise volume in 2021. Retail-related revenue represents approximately 80% of the total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (10%-15%), advertising services (5%), and other. International segments constitute 25%-30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.

    Rating
    Price Target
     

Related Tickers